Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A First-in-Class Compound Designed to Treat Metastatic Disease BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc.
